ABSTRACT
Objective To investigate the effect of capecitabine on serum tumor necrosis factor α( TNF-α) , interleukin-6 ( IL-6 ) , vascular endothelial growth factor (VEGF) and tumor biomarker (CEA,CA19-9 and CA125)levels in patients with advanced gastric cancer (AGC) and its efficacy and adverse reactions.Methods One hundred and sixty-one AGC patients from October 2012 to October 2014 in the hospital were randomly divided into control group (n=78) and observation group (n=83).The control group were treated with cisplatin in combination with docetaxel, while the observation group were treated with capecitabine on the basis of control group.The efficacy, adverse reactions and serum levels of TNF-α, IL-6, VEGF and tumor biomarkers were compared between two groups.Results There was no significant difference in effective rate between observation group and control group (50.6%vs.43.6%,χ2 =0.793,P=0.373) and disease control rate (78.3%vs.69.2%,χ2 =1.720,P=0.190).The half a year,1-year and 2-year survival rates in observation group were significantly higher than those in control group (90.4%vs.71.8%,78.3% vs.57.7%,60.2%vs.41.0%,all P<0.05).The gradeⅠ-Ⅱ adverse reactions of gastrointestinal tract in observation group was significantly higher than control group(P<0.05).After treatment, serum VEGF level in observation group was lower and serum TNF-α,IL-6 levels were higher than those in control group (P<0.05).The serum levels of CEA, CA19-9 and CA125 in observation group were lower than those in control group ( P <0.05 ) .Conclusion Capecitabine could improve immunologic function and inhibit tumor angiogenesis, which has an exact effect and increase survival rate of advanced gastric cancer patients with minor adverse reactions.Its mechanism may be regulating serum VEGF, TNF-α, IL-6 and tumor biomarkers of CEA, CA19-9 and CA125.